Skip to main content
Assets
Moderna logo
MRNA.NASDAQ
Moderna
Health Care · Biotechnology

Biotechnology company pioneering messenger RNA therapeutics and vaccines, gained prominence with COVID-19 vaccine development.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Moderna.

Historical AI Opinions

Moderna, Inc. (MRNA.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 11 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ThinkerAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+280.0%

MRNA.NASDAQ does not currently pay dividends

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.-23.85114.78253.42392.05530.68Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$28.5+14.0%Not Generated this time
$32.0+28.0%Not Generated this time
$38.0+52.1%Not Generated this time
$55.0+120.1%Not Generated this time
$62.0+148.0%Not Generated this time
$68.0+172.1%Not Generated this time
$75.1+200.1%Not Generated this time
$82.0+228.0%Not Generated this time
$88.0+252.0%Not Generated this time
$95.1+280.1%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

Moderna successfully navigates the post-pandemic transition, albeit with mixed results. The respiratory vaccine franchise (RSV, Flu/COVID combo) achieves commercialization but secures a modest, not dominant, market share, providing a foundational revenue stream that partially offsets declining Spikevax sales. The key personalized cancer vaccine (PCV) shows a statistically significant but clinically moderate benefit, leading to approval in a specific niche indication like adjuvant melanoma but failing to immediately unlock the broader oncology market. This partial success validates the platform's potential beyond infectious diseases but requires further long-term data. The company manages its cash burn effectively, slowly moving towards operational breakeven by the end of the forecast period. The stock price gradually appreciates, reflecting a successful but highly competitive company with a few key products and a promising, yet still unproven, broader pipeline.

2. Scenarios & Signals

2.1. Bull Case

Moderna's mRNA platform realizes its full potential. Its combined Flu/COVID and RSV vaccines capture dominant market share, establishing a stable, multi-billion dollar respiratory franchise. The pivotal catalyst is the unambiguous success of the personalized cancer vaccine (PCV) in partnership with Merck, showing a significant survival benefit in major cancer types like melanoma and lung cancer. This leads to rapid approval and blockbuster sales, transforming Moderna into a diversified biotech powerhouse. Further pipeline successes in rare diseases and latent viruses solidify its growth trajectory, leading to a major re-rating of the stock as the market prices in a platform capable of repeatedly generating revolutionary medicines. The company achieves sustained profitability and robust revenue growth, driving the market capitalization to levels reflecting its leadership in a new era of medicine.

2.2. Bear Case

Moderna fails to transition beyond its one-time COVID-19 success. Its respiratory vaccines disappoint commercially, facing intense competition from Pfizer, GSK, and others, resulting in underwhelming sales and market share. The most significant blow comes from the failure of the personalized cancer vaccine (PCV) program, which fails to meet its primary endpoints in Phase 3 trials, erasing the company's most promising long-term catalyst. With other pipeline candidates also facing setbacks or delays, confidence in the underlying mRNA platform evaporates. The company's substantial cash reserves are depleted by high R&D and SG&A expenses without new revenue streams to offset the burn. This forces dilutive financing rounds and a major strategic restructuring, causing the stock to trade down towards its net cash value.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 512Thinking Tokens: 3,228Response Tokens: 8,069Total Tokens: 11,809
Thinker modeThinker · no external search

This Thinker run did not use external web search. The model relied on the supplied research context and its internal reasoning.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.